| Cardiovascular Risk Management |
1 |
1 |
| Type 2 Diabetes Mellitus |
0 |
1 |
| Statins |
0 |
0.9 |
| Coronary Artery Disease (CAD) |
0 |
0.47 |
| SGLT2 Inhibitor |
0 |
0.9 |
| Lipids Management |
0 |
0.36 |
| Cardiovascular disease |
0 |
0.27 |
| Clinical Guidelines |
0 |
0.27 |
| Hypertension |
0 |
0.23 |
| CRISPR |
0 |
0.13 |
| Endocrinology |
0 |
0.13 |
| Geriatrics |
0 |
0.13 |
| Grant |
0 |
0.13 |
| Heart |
0 |
0.13 |
| Insurance |
0 |
0.13 |
| Jobs |
0 |
0.13 |
| Noninsulin Antidiabetic Drugs |
0 |
0.13 |
| Pandemic |
0 |
0.13 |
| Primary Care |
0 |
0.13 |
| Renin-Angiotensin System |
0 |
0.9 |
| Genomic Medicine |
0 |
0.07 |
| Revenue and Practice Management |
0 |
0.07 |